Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox.
L-buthionine (S,R)-sulfoximine (BSO) at a dose of 220 mg/kg of body weight/day showed an anti-Trypanosoma cruzi effect in infected mice, increasing their survival rate and decreasing the parasitemias and parasite burden in the hearts. Treatment with BSO plus nifurtimox caused an increase in the survival rate in comparison to the rates with treatment with each drug alone.
Faúndez
Mario
M
Program of Molecular and Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.
López-Muñoz
Rodrigo
R
Torres
Gloria
G
Morello
Antonio
A
Ferreira
Jorge
J
Kemmerling
Ulrike
U
Orellana
Myriam
M
Maya
Juan D
JD
D000208:Acute Disease; D000818:Animals; D019328:Buthionine Sulfoximine / Q000494:pharmacology* / Q000627:therapeutic use; D014355:Chagas Disease / Q000188:drug therapy* / Q000401:mortality / Q000469:parasitology; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D051379:Mice; D008807:Mice, Inbred BALB C; D009547:Nifurtimox / Q000494:pharmacology* / Q000627:therapeutic use; D015996:Survival Rate; D014344:Trypanocidal Agents / Q000494:pharmacology; D014349:Trypanosoma cruzi / Q000187:drug effects*
D014344:Trypanocidal Agents; D019328:Buthionine Sulfoximine; D009547:Nifurtimox